Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
In the era of immune checkpoint inhibitors, these real-world results indicate a promising role for racotumomab in the maintenance setting for advanced NSCLC. These findings provide a strong rationale for further investigation of racotumomab in the context of modern immunotherapy, particularly in combination trials with other immunomodulatory antibodies, along with the validation of clinical and biologic predictive biomarkers.
Authors
- Loipa Medel Pérez (ORCID: https://orcid.org/0000-0002-7587-3119)
- Haslen Cáceres Lavernia
- Soraida Cándida Acosta Brooks
- Leticia Cabrera Benítez (ORCID: https://orcid.org/0000-0003-4561-3081)
- Mayelín Troche Concepción (ORCID: https://orcid.org/0000-0001-5385-5940)
- Tania Crombet (ORCID: https://orcid.org/0000-0002-2550-7292)
- Meylán Cepeda Portales
- Daymys Estévez Iglesias (ORCID: https://orcid.org/0000-0003-1351-3975)
- Kirenia Camacho Sosa (ORCID: https://orcid.org/0000-0003-0497-7647)
- Mayra Ramos (ORCID: https://orcid.org/0000-0002-9058-3224)
- Carmen Elena Viada González
- S. Aleman
- Orestes Santos Morales (ORCID: https://orcid.org/0000-0002-9468-8402)
- M Salmon
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Center of Molecular Immunology (Cuba) (CU)
- University of Matanzas (CU)
- Hermanos Ameijeiras Hospital (CU)
- Hospital Oncológico Docente "Conrado Benítez García" (CU)
Publication Details
- Journal
- Vaccines
- Published
- 2025-10-07
- DOI
- https://doi.org/10.3390/vaccines13101035
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00